Add Row

Add Element

update

Sound Advice Audiology
(860) 663-6517

update

Add Element

Home
Categories
Main Website

April 15.2026

2 Minutes Read

Explore Innovations in Hearing Care at EUHA 2026 in Hanover

Event advertisement with hands symbolizing partnership in hearing loss treatment.

Netherlands Takes the Spotlight at EUHA 2026

The International Congress of Hearing Care Professionals, known as EUHA 2026, is set to feature the Netherlands as its partner country, marking an exciting opportunity for advancements in the field of audiology. Scheduled for October 14–16, 2026, in Hanover, Germany, this congress promises a rich program that highlights Dutch contributions to hearing care.

Driving Innovation in Hearing Loss Treatment

With the focus on the Netherlands, attendees can expect expert presentations from leading Dutch audiology specialists, showcasing innovative hearing aids, advanced treatments for tinnitus, and effective hearing loss solutions. This partnership highlights the Netherlands’ commitment to improving audiology services and provides a platform for sharing knowledge that can enhance patient care globally.

Build Connections and Opportunities

The proximity of Hanover—just over 200 kilometers from the Dutch border—makes this collaboration a natural fit and anticipates increased participation from Dutch exhibitors. This congress will not only feature a live zone for discussions but also an evening event on October 15, promoting networking opportunities among professionals from various regions.

Open Call for Contributions in Audiology

For those wishing to contribute, the call for papers is ongoing until March 31, 2026. This provides a chance for professionals to present their research and findings, facilitating dialogue within the community. Such interactions are vital for shaping future trends in audiology treatments and technologies.

Preparing for a Transformative Experience

Attendance at EUHA 2026 is not just about professional growth; it’s also an invitation to explore the latest innovations in hearing devices and therapies specifically designed for hearing loss and tinnitus management. Whether you’re a geriatric care manager, an ENT specialist, or a hearing aid dispenser, the knowledge gained here can significantly impact patient treatment outcomes.

Mark Your Calendars! Registration for tickets goes live in July. Those interested in exhibiting should act fast, as space is limited, and the last date to secure a spot is June 19, 2026.

If you're looking for cutting-edge solutions in audiology or wish to discuss hearing evaluations, don't hesitate to reach out for more information and visit our audiology services.

audiology clinic Vernon CT

0 Views

0 Comments

Write A Comment

Please complete the captcha to submit your comment.

Related Posts All Posts

04.06.2026

Revolutionizing Hearing Loss Treatment: Updates on Gene Therapies

Update The Latest Breakthroughs in Hearing Loss Gene Therapies Sensorion, a pioneering clinical-stage biotechnology company, has recently updated the medical community on its promising gene therapies aimed at addressing various forms of hearing loss. In a significant report, the company revealed the sustained efficacy of their lead candidate, SENS-501, through six-month follow-up data from their Audiogene Phase 1/2 Trial. This gene therapy specifically targets otoferlin-mediated congenital deafness, a condition often resulting in severe hearing impairment in infants and young children. Understanding the Audiogene Trial Outcomes The Audiogene trial evaluated the implantation of SENS-501 in infants aged between six months and just over two years who experience profound deafness due to genetic mutations. The findings recently reported at a six-month follow-up showed that two of three patients treated with a higher dose maintained noticeable improvements in pure-tone audiometry tests. This reinforces a suggested dose-response relationship, illuminating a potential pathway for broader therapeutic strategies in hearing loss treatment. Future Prospects: GJB2-GT (SENS-601) Along with SENS-501, Sensorion is developing GJB2-GT (SENS-601), which targets mutations in the GJB2 gene—the most prevalent cause of genetic congenital deafness. This program is significant as it aims to provide a solution for approximately 50% of cases of autosomal recessive non-syndromic hearing loss. Currently, GJB2-GT is on track to begin human trials following successful animal studies zoomed in by results regarding safety and distribution. The Impact of Gene Therapy As gene therapies begin to take center stage in treating hearing loss disorders, they present the potential to restore hearing capabilities in patients who have few to no existing treatment options. This is a particularly pressing issue given the increasing incidents of hearing impairment conditions worldwide. Occupational health directors and ENT specialists may find this information particularly relevant as they navigate treatment options for their patients. Why This Matters to Healthcare Professionals New Treatments Available: These therapies expand the horizon of treatment options for genetic hearing loss. Informed Care Decisions: Understanding emerging treatments helps healthcare providers offer informed guidance to patients and families. Ongoing Research and Collaboration: Sensorion's collaboration with institutions like the Necker Enfants Malades Hospital and the Institut Pasteur fortifies its credibility in advancing hearing health solutions. As new gene therapies evolve in their clinical efficacy and begin to see real-world applications, it’s essential for healthcare professionals to stay updated on these advancements. Hearing loss, particularly in pediatric populations, can hinder development and quality of life, making timely intervention critical. Looking Ahead: The Future of Hearing Health With therapeutic advancements like SENS-501 and SENS-601, the landscape of hearing health might be undergoing a revolution. The evolving approaches not only bring hope to families grappling with hearing loss challenges but also signify a commitment to innovative solutions in healthcare. If you are seeking more information on these advancements or have patients who might benefit from audiology services, do not hesitate to reach out for expert guidance. For more info visit: Sound Advice Audiology or Call: (860) 663-6517.

04.04.2026

Sonova's Move to Sell Sennheiser Consumer Hearing Business: What It Means for Hearing Health

Update Sonova Shifts Focus: Selling Sennheiser Consumer Hearing Business for Strategic Growth In a strategic move to consolidate its resources within the hearing health sector, Sonova Holding AG, a leading player in the audiology market, has announced its intention to sell the Sennheiser Consumer Hearing business. This decision comes as part of their broader strategy to prioritize investments in their core operations, specifically in hearing instruments and advanced cochlear implants, reflecting a clear shift towards sustainable growth in specialized areas. Re-defining Strategic Priorities CEO Eric Bernard emphasized that this renewed focus is designed to leverage Sonova's technological leadership while enhancing local execution. The new strategy revolves around three pivotal priorities: Innovate to Drive Adoption: Sonova aims to expand the design and form factors of its products, aligning them with modern lifestyles and aging trends. This includes incorporating artificial intelligence and advanced digital solutions across its offerings. Local Success through Multi-channel Strategies: By managing distribution comprehensively on a market-by-market basis, Sonova seeks to differentiate brand roles while enhancing operational synergies. Enhance Service and Operations: Prioritizing customer service will transform it into a critical driver of growth, supported by operational optimizations. Background: An Acquisition Leading to Divestment This shift follows Sonova's acquisition of Sennheiser’s consumer division in 2022, a deal valued at €200 million. Although this segment was seen as an opportunity to expand within the consumer electronics market, the realities of market dynamics indicated a significant divergence from Sonova's core business focus. Notably, Sennheiser’s operations have historically catered to audiophile audio solutions and premium home audio products, contrasting sharply with Sonova's intense focus on medical-grade hearing solutions. Current Implications for Consumers and the Market For consumers, day-to-day operations and product support under the Sennheiser brand will not change immediately. Continuing product development and warranty coverage will remain in effect while Sonova searches for a new buyer. This strategic divestment aligns with Sennheiser's own focus on audiophile and premium audio gear, indicating a potential future where Sennheiser's strong brand identity could thrive under new ownership. Looking Ahead: Potential Buyers and Industry Reactions The marketplace is abuzz with speculation regarding potential buyers, ranging from European firms to private equity groups and even rumors of interest from Asian conglomerates. The divide in industry opinion has been notable, reflecting anxieties and excitement about who might take over the iconic Sennheiser brand. Sonova’s decision underscores a larger trend within the healthcare sector, as companies gravitate towards their core competencies to drive innovation and growth. Its renewed commitment to audiology solutions stands as a testament to the ongoing evolution of consumer health technology. As the industry watches closely, questions linger about the implications of this sale for stakeholders including healthcare practitioners, audiology professionals, and patients alike. For actionable insights and health-related consultations, healthcare professionals are encouraged to reach out to local audiology services for tailored solutions. For more info visit: Sound Advice Audiology or call: (860) 663-6517

03.27.2026

Updated ABN for Audiologists: What Every Practitioner Should Know

Update What You Need to Know About the Updated ABN On March 13, 2026, the Centers for Medicare & Medicaid Services (CMS) released an updated Advanced Beneficiary Notice (ABN), replacing the previous version. This new form is effective until March 31, 2029, and practitioners are urged to discard any older forms to avoid confusion. The ABN is vital for healthcare professionals in informing patients about their potential financial responsibilities related to Medicare coverage. Understanding the Purpose of the ABN The ABN serves as an essential tool in the healthcare landscape, particularly for audiologists and other healthcare providers. It communicates to patients that certain services may not be covered by Medicare, allowing them to make informed decisions about their care options. With an updated ABN, providers can avoid potential billing issues and establish transparency with their patients. Critical Insights on ABN Usage for Audiologists According to recent updates, the ABN applies exclusively to traditional Medicare (Part B) beneficiaries, leaving out Medicare Advantage and other payer plans. This specificity highlights the importance of correctly identifying when and how to use the ABN in your practice. For most non-covered services, healthcare providers should consider using a Notice of Non-Coverage instead. New Sections Applied to the ABN The ABN form contains distinct sections for providers to fill out. Section D, for example, requires providers to list the services that may not meet the standard of medical necessity, while Section E should outline the reasons for this assessment. Utilizing these sections effectively can help practitioners communicate clearly with patients, mitigating any misunderstandings. Managing Patient Expectations and Responsibilities It’s crucial for healthcare professionals, especially within audiology, to manage patient expectations regarding coverage and costs effectively. By utilizing the ABN correctly, providers can ensure that patients understand their financial responsibilities before services are rendered. This proactive communication helps maintain trust and fosters a positive provider-patient relationship. What Does This Mean for Audiology Practices? With the new ABN form, audiologists will need to reassess their billing practices and ensure compliance with updated regulations. This means training staff on how to complete the ABN accurately and appropriately inform patients of their rights under Medicare. Adapting to these changes can avoid billing issues and enhance practice efficiency. Call to Action Wondering how this impacts your audiology practice or patient care in Vernon, CT? For more information on navigating these changes and how audiology services can help your patients, visit Sound Advice Audiology or call (860) 663-6517 today!

Explore Innovations in Hearing Care at EUHA 2026 in Hanover

Netherlands Takes the Spotlight at EUHA 2026

Driving Innovation in Hearing Loss Treatment

Build Connections and Opportunities

Open Call for Contributions in Audiology

Preparing for a Transformative Experience

Terms of Service

Privacy Policy

Core Modal Title